![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer
July 05, 2016 01:34 ET
|
DBV Technologies
MONTROUGE, France, July 5, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere
June 21, 2016 16:32 ET
|
DBV Technologies
Montrouge, France, June 21, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression
June 15, 2016 16:34 ET
|
DBV Technologies
Early-Stage Proprietary Model Suggests that Serum Biomarkers may help Monitor Treatment Progression with Viaskin Peanut
Additionally, Another DBV Data Presentation is Chosen as "Best of Poster...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT(r) Provides Sustained Protection Against Anaphylaxis
June 13, 2016 01:36 ET
|
DBV Technologies
DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis
MONTROUGE, France, June 13, 2016 (GLOBE NEWSWIRE)...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy
May 31, 2016 01:06 ET
|
DBV Technologies
BAGNEUX, France, May 31, 2016 (GLOBE NEWSWIRE) --
DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Announces Filing of 2015 "Document de Reference" and 2015 Annual Report on Form 20-F
April 28, 2016 17:34 ET
|
DBV Technologies
MONTROUGE, France, April 28, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy
March 04, 2016 13:41 ET
|
DBV Technologies
Results Presented at the AAAAI Meeting Showed CoFAR6 Met Primary Endpoint, With a Strong Response Observed in Children
Early Mechanistic Results are In-Line with DBV's Preclinical...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Announces Publication of Phase Ib Trial Results in the Journal of Allergy and Clinical Immunology (JACI) Supporting Safety and Tolerability of Viaskin(R) Peanut
February 25, 2016 16:56 ET
|
DBV Technologies
MONTROUGE, France, Feb. 25, 2016 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies: First Experimental Results for the Treatment of Colitis with Viaskin(r) will be presented at the Crohn's & Colitis Foundation of America's 2015 Advances in IBD Conference (AIBD)
December 10, 2015 01:36 ET
|
DBV Technologies
BAGNEUX, France, Dec. 10, 2015 (GLOBE NEWSWIRE) -- First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn's & Colitis Foundation of America's...
![DBV Technologies logo](/news-release/logo/311731/0/311731.jpg?lastModified=12%2F09%2F2016%2022%3A47%3A57&size=2)
DBV Technologies Announces Initiation of Phase III Study of Viaskin(r) Peanut for the Treatment of Peanut Allergic Children
December 07, 2015 17:05 ET
|
DBV Technologies
BAGNEUX, France, Dec. 7, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today...